Kabeshima Yasuo, Kubota Tetsuro, Watanabe Masahiko, Saikawa Yoshiro, Nishibori Hideki, Hasegawa Hirotoshi, Kitajima Masaki
Department of Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Anticancer Res. 2002 Nov-Dec;22(6A):3245-52.
Because thymidylate synthetase (TS) is a key enzyme in DNA synthesis, it has been used as a target for cancer chemotherapy.
We investigated the combined antitumor activity of raltitexed, 5-FU and UFT on human tumor xenografts in nude mice and examined changes in TS activity and 5-FU-bound RNA (F-RNA) levels. Human gastric (SC-1-NU) or colon (HT-29) carcinoma xenografts were transplanted subcutaneously into nude mice, and drugs administered intraperitoneally (raltitexed and 5-FU) or perorally (UFT) daily for 5 days, and repeated once after a 2-day interval.
The antitumor effects were mostly equivalent between the treatment groups despite the different drugs and sequence orders. TS inhibition rates correlated with the tumor inhibition rate, which was statistically significant, while F-RNA levels did not correlate with antitumor activity.
Our results indicated that the combination of fluoropyrimidine-related agents should be directed towards increased TS inhibition rather than increased F-RNA levels.
由于胸苷酸合成酶(TS)是DNA合成中的关键酶,它已被用作癌症化疗的靶点。
我们研究了雷替曲塞、5-氟尿嘧啶(5-FU)和优福定对裸鼠人肿瘤异种移植瘤的联合抗肿瘤活性,并检测了TS活性和5-FU结合RNA(F-RNA)水平的变化。将人胃癌(SC-1-NU)或结肠癌(HT-29)异种移植瘤皮下接种到裸鼠体内,药物通过腹腔注射(雷替曲塞和5-FU)或口服(优福定)给药,每天一次,持续5天,间隔2天后重复一次。
尽管药物和给药顺序不同,但各治疗组的抗肿瘤效果大多相当。TS抑制率与肿瘤抑制率相关,具有统计学意义,而F-RNA水平与抗肿瘤活性无关。
我们的结果表明,氟嘧啶相关药物的联合应用应旨在增强TS抑制作用,而非提高F-RNA水平。